The CSCs are a subpopulation of tumor cells that share certain similar characteristics with normal stem cells and are responsible for initiating and maintaining tumorigenesis and its recurrence (
22). CSCs can serve as appropriate therapeutic targets in cancer targeted therapy. Many pieces of evidence have indicated that BMI1 plays a significant role in proliferation, self-renewal, and differentiation of several types of stem cells and precursors cells (
23). BMI1 is required for not only self-renewal of different types of tissue-specific stem cells but also the proliferation of cancer cells (
24). As an epigenetic inhibitor, BMI1 inhibits Ink4a/ARF locus that codes P16Ink4a and P19ARF (the human homologue of P14ARF) via interaction with other components of PRC1 (
25) (
Figure 1). P16Ink4a and P19ARF are the upstream activators of Rb and P53 pathways, respectively (
26).
BMI1 at the center of the cancer stem cell signaling pathway. BMI1 inhibits ink4a/arf locus and the interaction between miR-330-3p and BMI1 can be taken as a potential biomarker for future investigation in CRC patients.
Many studies have demonstrated the increased expression of BMI1 at the mRNA and protein levels in CRC (
27). BMI1 mediates ubiquitination of histone and is essential for proliferation of colon cancer
in vitro and
in vivo (
28). It has been suggested that BMI1 plays a central role in maintaining colorectal cancer cells growth and tumor progression through regulation of self-renewal (
29). MiRNAs are considered key factors in cancer genetics and potentially can be used as anti-cancer drugs through their transfer to the cell (
30). In addition, miRNAs should be considered as promising targets for cancer diagnosis and treatments monitoring (
31). Although different techniques such as microarray are available to detect the miRNAs’ target genes, bioinformatics analysis is an inexpensive and convenient approach to conduct such studies. To the best of our knowledge, it has been shown that only miR-218 and miR-508-3p may inhibit BMI1 at the RNA or protein level in CRC (
32,
33).
Therefore, considering the significance of BMI1 in CSCs and the potential association between this molecule and different miRNAs in cancer, different bioinformatics tools were used to find miRNAs that suppress BMI1. To achieve this purpose, the known tumor-suppressing miRNAs in CRC were selected as candidates in bioinformatics analysis so that experimental investigations can be conducted to gain a better understanding of colorectal carcinogenesis. Besides, the importance of miRNAs as a potential biomarker in the study of colorectal cancer has been well demonstrated. According to the results of bioinformatics analysis in the current study, out of the investigated miRNAs, the highest score for targeting BMI1, as one of the markers of CSCs, was obtained for miR-330-3p. According to all databases used in this study, only miR-330-3p was found to target BMI1.
Most databases that were investigated in this study (apart from miRDB, miRanda, and FindTar3) gave the highest score for miR-330-3p. However, the score of this miRNA was acceptable in miRDB, miRanda and FindTar3 databases, as well. These high scores represent the stability of the seed sequence binding of miR-330-3p to 3’UTR of the BMI1 gene and high probability of targeting. Due to different algorithms and scoring schemes, some differences in the scores were noted among some databases; altogether, miR-330-3p was found to have the highest score. The expression of miR-330-3p, as a tumor suppressor, has been reported to decrease considerably in CRC tissues and cell lines (
34). Yan Li et al. study demonstrated that miR-330-3p induces apoptosis and inhibits proliferation via inhibiting cdc42 (
35).
The inhibitory role of miR-330-3p in gastric cancer was demonstrated by inhibiting Musashi-1 (MSI1) (
36). MSI1 is the marker of normal and cancer stem cells (
37). Therefore, given that BMI1 is the marker of colon cancer stem cells, the decreased expression of miR-330-3p is likely to be associated with the activation of colon cancer stem cells signaling pathways. According to the findings of the current study, the association between miR-330-3p and BMI1 expression can be investigated in experimental studies in order to evaluate its applicability as a biomarker in CRC (
Figure 1). Since the serum level of BMI1 increases in CRC patients (
38) and the miRNAs in the serum or plasma have been recently reported to be appropriate biomarkers with high specificity and sensitivity (
39), the simultaneous study of these two molecules in the serum or plasma of colorectal cancer patients can help achieve a double non-invasive biomarker panel.
4.1. Conclusion
Bioinformatics tools are one of the fastest and inexpensive approaches to find potential miRNAs targets. The results of the bioinformatics analysis of this study have shown the highest prediction scores for miR-330-3p in most miRNA-target prediction databases. BMI1 is involved in the function and survival of CSC; hence, the suppression of BMI1 expression with miR-330-3p would be not only a favorite therapeutic target in CRC targeted therapy but also valuable in a better understanding of the molecular mechanisms in CSC self-renewal and survival. Moreover, the expression evaluation of miR-330-3p and BMI1 in serum/plasma or tissues of CRC patients would be useful in biomarker studies. Altogether, the experimental validation of an association between BMI1 and miR-330-3p via techniques such as qRT-PCR, western blot, and luciferase assay is suggested.